Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Lou Gehrig’s Disease, also known as amyotrophic lateral sclerosis (ALS), is a rare, progressive neurodegenerative disorder affecting motor neurons, with an estimated global prevalence of 4-6 cases per 100,000 people. Despite its rarity, the disease imposes a substantial clinical burden due to rapid functional decline and limited treatment options. Lou Gehrig’s disease pipeline analysis by Expert Market Research highlights a growing portfolio of gene therapies, RNA-based medicines, and neuroprotective agents aimed at slowing disease progression and improving long-term patient outcomes.
-
Major companies involved in Lou Gehrig’s disease pipeline analysis include QurAlis Corporation, Clene Inc., and others.
-
Leading drugs currently in the pipeline include NUZ-001 and others.
-
The pipeline is driven by advances in antisense oligonucleotides, gene-editing platforms, neuroinflammation-targeting therapies, and precision biomarkers. Expanding research into RNA modulation, motor neuron preservation, and personalized medicine is accelerating the development of disease-modifying treatments designed to slow progression and improve long-term neurological outcomes.
Report Coverage
The Lou Gehrig’s Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Lou Gehrig’s disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Lou Gehrig’s disease. The Lou Gehrig’s disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Lou Gehrig’s disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Lou Gehrig’s disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Lou Gehrig’s disease.
Read more about this report - Request a Free Sample
Lou Gehrig’s Disease Pipeline Outlook
The pipeline is moving toward genetically targeted therapies and biomarker-based development. In April 2023, the FDA granted accelerated approval to Qalsody for SOD1-associated ALS, strengthening interest in antisense treatments for defined patient groups. Current programs are exploring therapies aimed at TDP-43, C9orf72, neuroinflammation, mitochondrial damage, and motor neuron protection. Future progress will depend on earlier diagnosis, reliable biomarkers, longer survival data, and trial designs suited to small, genetically diverse ALS populations with significant unmet treatment needs.
Lou Gehrig’s Disease Epidemiology
Lou Gehrig’s disease, or amyotrophic lateral sclerosis, remains rare but serious. The CDC estimates that close to 35,000 people in the United States have ALS, with about 5,000 new diagnoses each year. Most patients are diagnosed between ages 55 and 75, and the disease is slightly more common in men. Around 5% to 10% of cases are familial. National ALS Registry projections indicate US prevalence may exceed 36,000 cases by 2030 as population aging increases the diagnosed patient pool overall.
Lou Gehrig’s Disease – Pipeline Therapeutic Assessment
This section of the report covers the analysis of Lou Gehrig’s disease drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The Lou Gehrig’s disease pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Lou Gehrig’s Disease Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total Lou Gehrig’s disease clinical trials. Phase I (11.11%), Phase II (55.56%), and Phase III (33.33%), reflecting the distribution of drug candidates across the different stages of clinical development.
Lou Gehrig’s Disease Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the Lou Gehrig’s disease pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The Lou Gehrig’s disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Lou Gehrig’s disease. In June 2026, Trace Neuroscience initiated the Phase 1/2 FUNCTION ALS study in Europe. Patients were also dosed in the China-based LAUNCH ALS study. TRCN-1023 is an antisense therapy designed to restore UNC13A protein function.
Lou Gehrig’s Disease Clinical Trials – Key Players
The EMR report for the Lou Gehrig’s disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Lou Gehrig’s disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Lou Gehrig’s disease clinical trials:
- Tiziana Life Sciences Ltd.
- Celosia Therapeutics Pty Ltd.
- PhenoNet, Inc.
- Novotech (Australia) Pty Limited
- Neurizon Therapeutics Limited
- QurAlis Corporation
- Clene Inc.
- Trace Neuroscience, Inc.
- Denali Therapeutics Inc.
- Calico Life Sciences LLC
- Apellis Pharmaceuticals, Inc.
- Biohaven Ltd.
Lou Gehrig’s Disease – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Lou Gehrig’s disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Lou Gehrig’s disease drug candidates.
Drug: NUZ-001
NUZ-001 is a small molecule investigational therapy developed by Neurizon Therapeutics Limited for the treatment of Lou Gehrig's disease (Amyotrophic Lateral Sclerosis). The candidate is designed to protect motor neurons by reducing neuroinflammation and cellular stress while slowing disease progression. It aims to preserve neuromuscular function and improve patient outcomes. The ongoing clinical program is expected to be completed in 2027. Neurizon Therapeutics is an Australian biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders.
Drug: AAV9 Gene therapy
AAV9 Gene Therapy is an investigational gene therapy being developed by Trace Neuroscience, Inc. for Lou Gehrig's disease (Amyotrophic Lateral Sclerosis). It utilizes an adeno-associated virus serotype 9 (AAV9) vector to deliver therapeutic genetic material directly to motor neurons, targeting the underlying molecular mechanisms responsible for neuronal degeneration. The clinical study is expected to be completed in 2028. Trace Neuroscience specializes in precision genetic medicines, advancing innovative gene therapies for severe neurodegenerative diseases with significant unmet medical needs.
Drug: Ranolazine
Ranolazine is a small molecule repurposed therapy being evaluated by PhenoNet, Inc. for Lou Gehrig's disease (Amyotrophic Lateral Sclerosis). Originally approved for chronic angina, it is being investigated for its ability to reduce neuronal hyperexcitability and stabilize sodium channel activity, potentially slowing motor neuron dysfunction associated with ALS. The ongoing clinical trial is expected to be completed in 2027. PhenoNet is a collaborative clinical research network dedicated to accelerating innovative therapeutic development for patients living with ALS.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Lou Gehrig’s Disease Pipeline Insight Report
- Which companies/institutions are leading the Lou Gehrig’s disease drug development?
- Which company is leading the Lou Gehrig’s disease pipeline development activities?
- What is the current Lou Gehrig’s disease commercial assessment?
- What are the opportunities and challenges present in the Lou Gehrig’s disease pipeline landscape?
- What is the efficacy and safety profile of Lou Gehrig’s disease pipeline drugs?
- Which company is conducting major trials for Lou Gehrig’s disease drugs?
- Which companies/institutions are involved in Lou Gehrig’s disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Lou Gehrig’s disease?
Reasons To Buy This Report
The Lou Gehrig’s Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Lou Gehrig’s disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Lou Gehrig’s disease collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Amyotrophic Lateral Sclerosis Treatment Market
Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast
Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
